Clioquinol
From Wikipedia, the free encyclopedia
 |
|
|
Clioquinol
|
|
| Systematic (IUPAC) name | |
| 5-chloro-7-iodo-quinolin-8-ol | |
| Identifiers | |
| CAS number | |
| ATC code | D08 D09AA10 G01AC02 P01AA02 S02AA05 |
| PubChem | |
| Chemical data | |
| Formula | C9H5ClINO |
| Mol. mass | 305.499 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
PoM (UK); Rx (US) |
| Routes | topical only |
Clioquinol is a powerful anti-infective drug available for topical (Vioform) and internal (Enterovioform) use. It is neurotoxic in large doses and is associated with the SMON (subacute myelo-optic neuropathy) epidemic in Japan between 1957 and 1970 that affected over 10,000 people.
Recent research at UCSF [1] indicates Clioquinol appears to block the genetic action of Huntington's disease in mice and in cell culture.
Evidence from phase 2 clinical trials suggested that clioquinol could halt cognitive decline in Alzheimer's disease. This led to development of analogs including PBT2 as potential therapeutic compounds for the treatment of Alzheimer's disease.
[edit] External links
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
